Abstract: Purpose/Background: The objective of this study was to determine whether a novel α7 nicotinic acetylcholine receptor partial agonist improves cognition during nicotine withdrawal and improves abstinence rates. To do so, the effect of the α7 nicotinic acetylcholine receptor partial agonist, encenicline, on cognition and abstinence was evaluated when given as monotherapy and when combined with transdermal nicotine patch (nicotine replacement therapy [NRT]).
C
igarette smoking remains the leading preventable cause of death in the developed world. Smoking is estimated to cause more than 440,000 deaths in the United States annually and more than $193 billion in annual health-related economic losses. 1 Approximately half of the world's current daily cigarette smokers who do not quit will die prematurely of causes that could be prevented by treatment of their addiction to tobacco-delivered nicotine. 2, 3 While pharmacotherapy is universally recommended for smoking cessation, 4 and first-line cessation aids double to triple sustained abstinence rates over placebo, [5] [6] [7] [8] [9] [10] [11] studies have consistently found that 60% to 70% of smokers fail to attain abstinence with available therapies on any given attempt. [12] [13] [14] [15] [16] Reducing smoking prevalence by increasing cessation among current smokers is critical in reducing tobacco-related mortality in the future.
Cognitive deficits are commonly experienced during nicotine withdrawal and may increase the likelihood of failure to attain abstinence and early relapse. "Difficulty concentrating," as noted in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association, 2013), is commonly endorsed in prospective studies of withdrawal. 17, 18 Behavioral impairments with withdrawal have been most commonly found in the domains of sustained attention and working memory [19] [20] [21] and are reversed by nicotine re-exposure, thus supporting the causal role of nicotine abstinence on emergent deficits. [22] [23] [24] [25] [26] Rodent models using the 5-choice serial reaction time (RT) task 27, 28 and human models using measures of sustained visual attention 24, [29] [30] [31] [32] [33] [34] find increased omissions, decreased response accuracy, and increased variability in response speed within the first few hours of nicotine abstinence. Abstinence-induced impairments are also found on visual working memory tasks, 24, [35] [36] [37] [38] particularly as cognitive load increases. 39 These deficits are hypothesized to be modulated by decreased activation in executive control regions (eg, dorsolateral prefrontal cortex) 35, [40] [41] [42] [43] and an overall weaker inhibition of the default mode network during abstinence, 44, 45 as well as activity at the α7 nicotinic acetylcholine receptor (nAChR). 46 Further, cognitive deficits emergent during nicotine withdrawal predict relapse to smoking, [47] [48] [49] [50] [51] likely due to a combination of processes including negative reinforcement (ie, resumption of nicotine quickly alleviates cognitive deficits), drug-reward bias (ie, increased salience of drug stimuli), and goal and skill interference (ie, cognitive skills impaired by abstinence underlie effective use of coping skills). 52 For example, working memory deficits following 3 days of abstinence predict cessation outcomes among untreated smokers. 49, 50 One of the mechanisms of action of smoking cessations aids such as varenicline may be amelioration of withdrawal-associated cognitive impairment, 53, 54 supporting the hypothesis that cognitive-enhancing agents may improve smoking cessation rates.
This project aimed to discover whether a novel compound, targeting cognitive symptoms that worsen during early withdrawal from nicotine and are associated with early relapse, can ameliorate these symptoms and whether this, in turn, improves smoking cessation outcomes. To do so, we conducted a phase IIb trial of the effects of the selective α7 nAChR agonist, encenicline (EVP-6124; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide), as monotherapy and when combined with transdermal nicotine patch (nicotine replacement therapy [NRT]), on cognitive performance during early nicotine abstinence and on abstinence rates. α7 Nicotinic acetylcholine receptors are 1 of 2 principal nAChRs in the brain. They are ligand-gated cation channels, highly expressed in regions involved in cognitive function including hippocampus, cortex, and subcortical limbic regions. 55 α7 Nicotinic acetylcholine receptors are associated with cholinergic, dopaminergic, and glutamatergic transmission 56, 57 and are thought to mediate the procognitive effects of nicotine. α7 Nicotinic acetylcholine receptors are less sensitive to nicotine's effects than the more common neuronal α4β2 nAChRs. 58, 59 Typical doses of NRT, for example, a 21-mg patch, replace only 60% of the nicotine taken in by a 1-pack-per-day smoker, and the kinetics of NRT produce lower peak nicotine concentrations than smoked tobacco. Thus, it is likely that recently abstinent smokers using NRT experience reduced α7 nicotinic receptor stimulation than while smoking. Selective α7 nAChR agonists 60 have shown procognitive effects in animals, [61] [62] [63] [64] healthy volunteers, 65, 66 and adults with schizophrenia. [66] [67] [68] [69] Addition of an α7 nAChR agonist could restore α7 activity during early abstinence and may improve cognitive and abstinence outcomes when combined with NRT, which would primarily bind the high-affinity α4β2 receptors and blunt withdrawal symptoms and craving.
Encenicline is a potent α7 nAChR agonist that has good oral bioavailability and enters the brain readily (see Prickaerts et al 70 for compound structure). Encenicline is an antagonist of the serotonin 3 (5-HT 3 ), serotonin 2A (5-HT 2A ), and 5-HT 2B receptors and has very limited or no activity on other receptors. 70 At higher concentrations, it is a positive modulator of the α4β2 subtype nAChR. In a study of healthy adults, encenicline was found to be well tolerated, detectable in plasma at single doses between 1 and 180 mg, have linear kinetic effects with maximum plasma concentration occurring between 5 and 8 hours, and have a halflife of 54 to 62 hours. 66 The pharmacokinetic profile of the drug was found to be impacted by body weight but not food. 66 Studies in animals suggest that the major metabolic pathways for encenicline involve oxidation, glucuronide, and sulfate conjugations, whereas the minor pathway involves dechlorination and O-methylation. Human studies indicate low hepatic clearance compared with animals. Chances of drug interactions via cytochrome P450 enzymes are suspected to be low; however, other mechanisms of degradation are not yet known (EVP-6124 Investigator's Brochure, version 5.0).
Several studies support the procognitive effects of encenicline. Nonclinical trials support the efficacy of encenicline at improving visual recognition memory 70 and attention, vigilance, and impulsivity. 62 Phase 1 studies with encenicline in healthy young volunteers 66 as well as phases 1 and 2 studies in subjects with schizophrenia taking atypical antipsychotics 67, 68 and subjects with Alzheimer disease with or without concomitant acetylcholinesterase inhibitor medication 71 have provided evidence of cognitive enhancement as assessed with the CogState battery. It is postulated that the effects of encenicline on improved cognition may be mediated by modulation of multiple neurotransmitter systems including dopamine, acetylcholine, and glutamate in the prefrontal cortex and other brain regions. 72 The primary aims of this trial were to establish whether encenicline monotherapy or combination therapy with NRT (1) can ameliorate withdrawal-associated cognitive impairment and (2) is associated with improved 12-week smoking cessation outcomes. We hypothesized that subjects randomized to encenicline + NRT patch or encenicline + placebo patch would demonstrate superior performance on a cognitive battery and have lower relapse rates compared with those assigned to placebo capsule + NRT or placebo capsule + placebo patch.
MATERIALS AND METHODS
All participants gave written informed consent to the Partners' Human Subjects Review Committee-approved protocol prior to initiating study procedures. Study procedures were conducted between January 2012 and September 2015 at the Center for Addiction Medicine and the Depression Clinical and Research Program at the Massachusetts General Hospital in Boston, Mass. Study procedures were terminated prematurely because of a US Food and Drug Administration clinical hold on all clinical trials of encenicline due to reports of serious gastrointestinal adverse events (AEs) in study participants with dementia of the Alzheimer type. The trial was concluded with 41% of planned enrollment.
Study Population
Eligible participants were otherwise healthy, aged 18 to 65 years, who smoked at least 10 cigarettes per day during the prior 6 months, had expired carbon monoxide (CO) of 10 parts per million (ppm) or greater at screening, reported smoking within 30 minutes of awakening, were fluent in English, and were willing to set a quit date within 4 weeks of enrollment. Those who had an alcohol or other drug use disorder within the past 6 months; had a lifetime psychotic, bipolar, or pervasive developmental disorder or current major depressive disorder; or were pregnant or lactating were excluded. See Supplemental Digital Content 1, http://links.lww.com/ JCP/A509, for full inclusion/exclusion criteria. Participants were recruited using local media advertisement and physician referral.
Study Design
This was a phase IIb, randomized, double-blind, placebocontrolled, parallel-group, 2 Â 2 design treatment trial designed to evaluate the effects of encenicline monotherapy and combination therapy with NRT patch on cognitive and abstinence outcomes in smokers with nicotine use disorder. Eligible participants participated in 2 baseline cognitive assessments: a satiated (nonabstinent) baseline and a 24-hour abstinent baseline. Participants were considered to have achieved 24-hour abstinence if they reported not smoking for 18 to 24 hours and had an expired CO of less than 10 ppm in those smoking less than or equal to 1 pack per day and CO of less than 15 ppm in those smoking more than 1 pack per day. Participants who did not arrive in an abstinent state by these criteria were provided another opportunity within 10 days to complete the abstinent baseline assessment. Participants who had 2 failures to achieve abstinence for the abstinent baseline assessment were not eligible for randomization and were referred for clinical smoking cessation treatment.
Eligible participants who completed both satiated and abstinent baseline assessments were randomized to 1 of 4 treatment groups, using a stratified 16-block randomization procedure. Stratification variables were sex and severity of nicotine dependence based on the Fagerström Test for Cigarette Dependence 73 total score obtained at screening (score of ≥6 [severe dependence] or score of <6 [low to moderate dependence]).Treatments included (1) encenicline 1-mg capsule plus NRT transdermal patch (encenicline + NRT), (2) encenicline 1-mg capsule plus placebo patch (encenicline + PP), (3) placebo encenicline capsule plus NRT transdermal patch (PC + NRT), and (4) placebo encenicline capsule plus placebo patch (PC + PP). Immediately following completion of the abstinent baseline assessment, randomization status was assigned, study medication was distributed, and the first dose of study drug was observed being taken in the clinic, and the patch was placed with instructions for future placement and use.
Assessments during the treatment phase were conducted at weeks 1, 2, 4, 6, 8, 10, and 12. At week 12 or early termination, all participants were asked to complete a final assessment including those who prematurely discontinued study treatments. This study also included a 1-and 2-week follow-up safety assessment (data not presented).
Study Interventions
During the 12-week treatment period, participants ingested an oral dose (one capsule) of study drug (encenicline 1 mg or identical-appearing PC) in the morning and applied 1 transdermal patch (NicoDerm CQ or identical-appearing PP) daily on days 1 to 42, on a taper schedule involving the use of 21 mg/d for weeks 1 through 3, 14 mg/d for weeks 4 and 5, and 7 mg/d for week 6 (last dose on day 42 ± 3 days). Adherence to study drug was assessed by recording the number of capsules and patches dispensed and returned at every study visit. Participants were offered brief (<10 minutes) cognitive behavioral therapy sessions at each of 9 study visits during double-blind treatment based on the Freedom From Smoking curriculum from the American Lung Association (http://www.ffsonline.org/).
Outcome Measures
The primary cognitive end points were performance on the Conners Continuous Performance Task (CPT), a measure of attentional control and response inhibition, 74 and the N-back task, a standard measure of working memory under varying levels of task demand. These measures are sensitive to the effects of nicotine, 19, [75] [76] [77] [78] [79] [80] abstinence, 49, 81, 82 and other nAChR agonists. 53 During the CPT, participants were asked to press a button as quickly as possible whenever a letter appeared on a computer screen unless that letter was an "X." Hit RT and hit RT SE were primary outcomes of interest. On the N-back task, participants were asked to indicate if a stimulus presented one at a time sequentially was identical to the stimulus presented N items prior, where N equals 1, 2, or 3. 83 N-back outcomes of interest were RT on 2-and 3-back levels. Cognitive tests were performed at the satiated and abstinent baseline visits and the study week 1, 2, 6, and 12 visits.
The primary smoking-related end point was self-report of 7-day point prevalence tobacco abstinence using the Timeline Follow-Back method, 84 biochemically verified by expired air CO levels of less than 10 ppm and urine cotinine of 50 ng/mL or less. 85 
Safety Assessments
Safety assessments included physical examinations, routine laboratory assessment, 12-lead electrocardiogram, concomitant medications, urinalysis and screen for illicit drugs, and treatment-emergent AEs. Safety assessments also comprised nicotine craving and withdrawal assessments, including the Wisconsin Smoking Withdrawal Scale (WSWS) 86 and the Tiffany Questionnaire of Smoking Urges (TQSU), 87 as well as psychiatric measures such as the Positive and Negative Affect Scale, 88 Center for Epidemiologic Studies-Depression, 89 and Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. 90 To monitor safety during treatment, electrocardiogram was conducted at baseline and weeks 1, 2, 6, and 12; laboratory tests were conducted at weeks 1, 4, 6, and 12. If clinically significant laboratory test abnormalities emerged during treatment, participants were notified and either discontinued if deemed appropriate or advised to seek care as appropriate through their regular physician.
Statistical Analysis
Analyses were conducted with the modified intent-to-treat population that included participants who received at least 1 dose of study medication and returned for at least 1 postbaseline assessment (n = 160). To examine changes in cognitive performance from satiated to abstinent baseline assessments, paired t tests were conducted separately for each cognitive measure among those who achieved overnight abstinence.
The cognitive models to study the average effect of treatment on cognitive performance over 12 weeks after adjusting for baseline included only data from visits at which the participant had verified 7-day point prevalence abstinence. Marginal structural models were conducted to correct for the fact that abstinent patients were not a random subgroup of the sample.
91,92 Significant average effects were followed up at each study visit using the same model. In the marginal structural models, parameters were estimated using a derived weight, which was the inverse probability of being abstinent, multiplied by the group-specific abstinence rate. The predicted probability at week 1 was estimated using logistic regression on identified predictors from forward selection with 0.1 as entry P value. Candidate predictors had known association with abstinence and included age, sex, education level, expired CO, total Center for Epidemiologic Studies-Depression score, IQ, lifetime problem alcohol use, age at smoking initiation, Fagerström Test for Cigarette Dependence total score, total WSWS score, total TQSU score, desire to quit smoking, length of longest prior abstinence, and negative and positive affect scores (Positive and Negative Affect Scale). Forward model selection identified total TQSU, expired CO, negative affect score, and longest duration of abstinence as significant predictors of abstinence (area under the curve = 0.72). After week 1, logistic regression with repeated measures was conducted to assess the predicted probability of abstinence, which included total TQSU, expired CO, negative affect, and longest duration of abstinence as covariates, as well as the effect of time and prior abstinence status. Effects were estimated using generalized estimating equations with an autoregressive variance-covariance matrix. Final models predicting probability of being abstinent at week 1 and after week 1 are presented in Supplemental Digital Content 2, http://links. lww.com/JCP/A510.
Abstinence models included all participants and assumed nonabstinence when there were missing abstinence data at any visit. Logistic regression with repeated measures was used to study the average drug effect on probability of abstinence. Effects were estimated using generalized estimating equations with an unstructured variance-covariance matrix. Significant average effects were followed up at each study visit using the same model. Data were analyzed using SAS version 9.4 (SAS Institute, Cary, NC). An α of P < 0.05 (2-tailed) was considered statistically significant.
RESULTS

Study Sample
Of 346 smokers who consented to participate in the study, 240 were eligible; 181 completed the satiated and overnight abstinent baseline cognitive assessments, were randomized, and received study medications; and 160 (88.4% of those randomized) completed at least 1 postrandomization study visit and were included in the analysis (see CONSORT Diagram, Supplemental Digital Content 3, http://links.lww.com/JCP/A511). The groups were well matched on demographic, educational, smoking, psychiatric, and substance use characteristics (Table 1 ). There was no group difference in study visit attendance (encenicline + NRT: mean, 7.7 [range, [3] [4] [5] [6] [7] [8] [9] ; encenicline + PP: mean, 6.5 [range, [3] [4] [5] [6] [7] [8] [9] ; PC + NRT: mean, 7.4 [range, [3] [4] [5] [6] [7] [8] [9] ; and PC + PP: mean, 7.0 [range, 2-9]). 
Cognitive Effects
Cognitive Effects of Encenicline
There was no beneficial cognitive effect for encenicline monotherapy compared with placebo when averaged across the 12-week *Enrolled, not analyzed < encenicline + NRT patch, encenicline + placebo patch, placebo capsule + NRT patch, placebo capsule + placebo patch; P < 0.02.
All values are means and SDs at screening unless otherwise noted. Unless indicated, there were no significant between-group differences in baseline characteristics in groups.
ASRS indicates Adult ADHD Self-report Scale, for which scores 24 (Table 2) .
There was also no cognitive benefit observed of encenicline when added to NRT compared with PC + NRT when averaged across the 12-week trial. On the CPT RT, those assigned to encenicline + NRT performed slower on average compared with those on PC + NRT, and there were no significant treatment effects on N-back performance (Table 2) .
Cognitive Effects of NRT
A beneficial effect of NRT added to encenicline was observed over encenicline + PP (Supplemental Digital Content 5, http://links. lww.com/JCP/A513). Those on encenicline + NRT performed faster than did those on encenicline + PP on the 2-back level of the N-back, and this effect was greater than the effect of NRT alone (ie, PC + NRT vs PC + PP). On average, those randomized to PC + NRT were not different from those on PC + PP on any cognitive measure when averaged across the 12-week trial (Table 3) .
Abstinence Outcomes
At week 4 prior to the NRT taper, 7-day point prevalence abstinence rates were highest for those on NRT alone (44.7%), followed by NRT with encenicline (40.0%), PC + PP (19.5%), and encenicline alone (17.1%).
When averaged across the 12-week trial, abstinence rates were not higher with encenicline than with placebo when used as monotherapy (encenicline + PP vs PC + PP; χ 2 = 0.54, P = 0.46; 95% confidence interval [CI], 0.26-1.84) or when combined with NRT (encenicline + NRT vs PC + NRT; χ 2 = 0.60, P = 0.44; 95% CI, 0.63-2.95; see Fig. 1 for abstinence rates by week). However, adding NRT to encenicline significantly improved odds of abstinence relative to encenicline alone; those on encenicline + NRT had a 3.24 times greater odds of being abstinent compared with those on encenicline + PP (χ 2 = 6.85, P = 0.009; 95% CI, 1.34-7.82), an effect that was significant at weeks 2 (odds ratio [OR], 4.04; χ 2 = 7.31, P = 0.007; 95% CI, 1.47-11.09), 4 (OR, 3.59; χ 2 = 5.58, P = 0.02; 95% CI, 1.24-10.35), 6 (OR, 4.86; χ 2 = 9.78, P = 0.002; 95% CI, 0.59-2.57), and 10 (OR, 3.28; χ 2 = 4.96, P = 0.03; 95% CI, 1.15-9.32; P > 0.06 for this comparison at weeks 8 and 12; Fig. 1 ).
Although 7-day point prevalence abstinence rates were higher at week 4 prior to the NRT taper in the NRT-only control than placebo (PC + PP; P = 0.01), abstinence rates were not higher for PC + NRT versus PC + PP for the entire study period that included 2-week NRT taper and 6 weeks with no NRT (χ 2 = 1.28, P = 0.26; 95% CI, 0.69-4.00).
Safety
There were 13 AE categories in which at least 5% of participants reported an occurrence at any time point during the 12-week All effects are estimated from weighted abstinent patients. *Evaluating this effect by week, those on encenicline + NRT performed slower at weeks 6 (χ 2 = 4.99, P = 0.03; 95% CI, 2.29-35.18) and 12 (χ 2 = 12.78, P = 0.0003; 95% CI, 18.43-63.14; P > 0.25 at other time points) than did those on placebo capsule + NRT. † Evaluating this effect by week, those on encenicline + placebo patch performed faster than did those on placebo capsule + placebo patch at week 2 (χ 2 = 7.26, P = 0.007; 95% CI, −199.89 to −31.55) and slower at week 6 (χ 2 = 14.99, P = 0.0001; 95% CI, 100.89-307.74; P > 0.09 at other time points). (Table 2) . Constipation was the most common AE. Headache, stomachache, and muscle spasm were more common in the EVP arms than in the placebo pill arms of the trial. There were no serious AEs (Table 4) .
DISCUSSION
The selective α7 nAChR partial agonist, encenicline, at a dose of 1 mg/d, was not effective for improving attention or memory performance during early abstinence or for improving abstinence rates when given as monotherapy or in combination with NRT. Nicotine replacement therapy patch, during active dosing prior to dose taper, had modest positive benefits on cognition and on abstinence when given as monotherapy and in combination with encenicline, providing a positive control for the negative findings for encenicline. 75, [93] [94] [95] It is expected that NRT did not have a positive effect on cognition over the entire time course of the trial because NRT was dosed for only 6 weeks with a 2-week taper and discontinued for the final 6 weeks of the trial.
Results are unexpected, given previous reports of procognitive effects of encenicline. Procognitive effects of encenicline have been reported in preclinical work in which single 70 and chronic doses 96 improved memory performance on delay-dependent forgetting tasks. In clinical trials, adjuvant encenicline showed significant procognitive effects on cognitive and functional measures in medical 71 and psychiatric 68 populations. α7 Nicotinic cetylcholine receptor agonists, GTS-21, SSR180711, and S24795, improve learning and memory performance in animals (for review, see [97] [98] [99] ) and humans. 65, 100 Varenicline, a partial α4β2 agonist and full α7 nAChR agonist, also improves nicotine withdrawal-associated deficits in learning and memory. 53, 101 Although encenicline has been shown to have procognitive effects at low single-dose nanomolar concentrations, 70 it is possible that the 1-mg dose administered in this study was insufficient when chronically administered and that higher doses may be required to obtain procognitive effects in this population. Barbier and colleagues 66 demonstrated that encenicline was well tolerated up to doses of 180 mg and speculated that 2 to 4 mg/d may be needed to optimize procognitive effects. Effects of receptor desensitization or tolerance are an unlikely explanation for the negative findings, as cognitive improvement was not evident with encenicline monotherapy or combined with NRT even in study weeks 1 and 2, and prior studies do not support tolerance effects with chronic dosing of nAChR agonists, including encenicline. 96, 102, 103 Further, the cognitive tasks were chosen to minimize practice effects and were given to all groups at the same time intervals; therefore, any practice effect should be comparable across groups and not influence findings. Given that we did not observe a significant placebo or practice effect on cognitive task performance, these factors are unlikely to explain the negative finding for encenicline on withdrawal-associated attention and memory. In addition, we observed significant worsening of cognition after overnight abstinence, with small effect sizes (Cohen d ranging from 0.16 to 0.30), comparable to the degree of worsening observed in other studies. 21, 104, 105 Thus, it is unlikely that insufficient test sensitivity and/or a ceiling effect explained the lack of effect of encenicline on cognition.
Study findings also do not support encenicline, at a dose of 1 mg/d, as an effective smoking cessation aid. Subjects randomized to encenicline alone did not have better odds of achieving abstinence over 12 weeks than did those on placebo. Conversely, abstinence rates were numerically but not significantly lower with encenicline alone than with placebo. Further, when added to NRT, encenicline did not enhance the effect of NRT. However, NRT increased the odds of abstinence 3-fold when combined with encenicline compared with encenicline alone, replicating a large body of research supporting the efficacy of NRT when combined with other treatments 15, 106, 107 and improving confidence in the null findings of encenicline as a therapeutic agent for smoking cessation. While the odds of abstinence were not higher for NRT relative to placebo for the entire period that included NRT taper and no NRT, abstinence rates were more than doubled with active rather than placebo NRT, and abstinence rates were higher in subjects assigned to NRT versus placebo at week 4 prior to the NRT taper. It is also noteworthy that the placebo response, averaging 21.6% abstinence, was rather high compared with other trials assessing abstinence over the time frame, 15, 106, 107 which may have minimized our ability to detect abstinence differences with both NRT conditions. This high placebo response may potentially be due to the requirement for overnight abstinence prior to randomization and inclusion of an effective smoking cessation cognitive behavioral therapy intervention for all participants.
Findings should be interpreted in the context of the following limitations. because of a US Food and Drug Administration clinical hold on clinical trials of encenicline, enrollment was halted prior to the target enrollment of 96 participants per arm, resulting in reduced power to detect treatment effects on cognition and abstinence or moderators of treatment effects, such as sex, which has been shown to influence the pharmacokinetic profile of encenicline. 66 The rapid NRT taper may underlie the rapid relapse rate observed in the NRT arms but is unlikely to have impacted our ability to detect an effect of encenicline, as there was no evidence that encenicline enhanced cognition or abstinence prior to the NRT taper.
To our knowledge, this was the first study to evaluate a putative α7 agonist cognitive-enhancing agent for smoking cessation. Although encenicline, at the dose tested, did not improve cognitive performance during early nicotine withdrawal, further efforts are warranted to test the hypothesis that a cognitive-enhancing agent can ameliorate withdrawal-associated cognitive impairment and, through this mechanism, may improve abstinence rates either alone or in combination with a first-line pharmacotherapeutic smoking cessation aid.
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